Developer docs
API playgroundTry for free, no card

Search company profiles

PRF Technologies

Full company profile

uuid00ypdnw

Namestring
PRF Technologies
Legal namestring
PRF Technologies Ltd.
Websiteurl
prf-tech.com
Company typeenum
Public
Founded yearint
2026
Descriptiontext

PRF Technologies Ltd. (NASDAQ: PRFX), formerly PainReform Ltd., is an Israel-based, publicly traded diversified company operating two distinct platforms: specialty pharmaceutical drug-delivery therapies and AI-driven solar asset analytics. The company rebranded from PainReform in January 2026 following shareholder approval to reflect its strategic expansion. The pharmaceutical portfolio is anchored by PRF-110, a proprietary oil-based extended-release formulation of ropivacaine designed to be deposited directly into the surgical wound bed to provide sustained 72-hour local analgesia with a single intraoperative administration, and OcuRing-K, a patent-protected bio-erodible sustained-release intraocular ring delivering ketorolac for post-cataract surgery inflammation control, developed through majority-owned subsidiary LayerBio, Inc. Both programs target the FDA 505(b)(2) regulatory pathway.

The AI platform comprises DeepSolar, an AI-driven SaaS for utility-scale solar plants that combines production forecasting, storage optimization, imbalance risk management, and real-time market decision support using plant-level operational data and localized weather modeling; DeepSolar Predict, a next-generation revenue optimization module extending coverage to wind and battery storage assets; and Smart TDD, an analytics-driven technical due diligence service for solar asset lifecycle events. DeepSolar is an active participant in the NVIDIA Connect Program and has a pending patent application for solar plant micro-climate forecast modeling. Pharmaceutical products remain pre-commercial pending FDA approvals; the FDA cleared the IND for OcuRing-K Phase II in April 2026, and PRF-110 reported positive preclinical head-to-head data versus ZYNRELEF in May 2026.

The company monetizes the solar platform through annual SaaS subscriptions for DeepSolar, one-time professional services fees for Smart TDD engagements, and a channel partnership with Blade Ranger Ltd. targeting 150MW+ enterprise portfolios. Named commercial deployments include SaaS agreements with Shikun & Binui Energy (71 MW Satu Mare, Romania) and Econergy (92 MW Romania pilot), plus a Smart TDD engagement with EDF Power Solutions Israel. As of December 31, 2025, PRF Technologies held approximately $4.1M in cash, cash equivalents, short-term deposits and restricted cash against a FY2025 net loss of $4.8M (improved from $14.6M in FY2024), positive working capital of approximately $2.0M, and completed approximately $4.0M in ATM equity issuances during 2025. No revenue is disclosed. The company is headquartered in Tel Aviv with an investor relations office in New York and an R&D presence in Boston via LayerBio.

Short descriptiontext

PRF Technologies (NASDAQ: PRFX) is an Israel-based diversified company developing specialty pharmaceutical drug-delivery therapies (PRF-110, OcuRing-K via LayerBio) and AI-driven SaaS for utility-scale solar asset analytics (DeepSolar). Pharmaceutical programs remain pre-commercial; DeepSolar generates early enterprise SaaS revenue.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTel Aviv, Israel
HQ citystring
Tel Aviv
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
extended-release pharmaceuticals, post-operative pain therapy, ophthalmic drug delivery, solar asset analytics, renewable energy forecasting
Industry2 codes
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYEUACAGAI
Performance Optimization & Analytics (Monitoring, Forecasting, Aerial Thermography, IV Curves)
Energy, Utilities & Environment/Electric Power Generation/Solar Power Generation (Utility-Scale PV & CSP)
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Software Publishers513210
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Prepackaged Software7372
Product category
Specialty Pharmaceuticals
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1DeepSolar SaaS Subscriptions
TypeSubscription Recurring
Description

SaaS subscription model for AI-driven solar analytics platform. Customers pay recurring subscription fees for access to DeepSolar platform providing continuous analytics, performance monitoring, and operational insights for solar assets.

tipranks.com
2Solar Technical Due Diligence Services
TypeProfessional Services
Description

One-time service fees for technical due diligence engagements including commissioning verification, warranty expiry assessments, underperformance diagnostics, and asset acquisition due diligence using Smart TDD analytics.

prf-tech.com
3Pharmaceutical Product Sales (Future)
TypeOne Time License
Description

Revenue from sale of FDA-approved pharmaceutical products including PRF-110 for post-operative pain and OcuRing-K for cataract surgery. Products will be marketed through healthcare providers upon regulatory approval via 505(b)(2) pathway.

prf-tech.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Pricing details1 tier
1Enterprise SaaS for Utility-Scale Solar (150MW+)
ModelSubscriptionBilling cadenceAnnual
Notes

Targeting multiple large-scale commercial engagements, each with minimum scope of 150 megawatts. Subscription-based pricing model for DeepSolar AI analytics platform.

finance.yahoo.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1PRF-110
Description

Oil-based, viscous clear solution deposited directly into surgical wound bed for localized and extended post-operative analgesia. Based on the local anesthetic ropivacaine.

prf-tech.com
+4 more records
Core offering1 text field

PRF Technologies develops proprietary extended-release drug-delivery platforms for specialty pharmaceuticals—PRF-110, an oil-based ropivacaine formulation for post-operative analgesia, and OcuRing-K, a bio-erodible intraocular ring for cataract surgery—and operates DeepSolar, an AI-driven SaaS platform providing forecasting, diagnostics, storage optimization, and technical due diligence for utility-scale solar assets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Sustained 72-hour analgesic activity comparable to approved ZYNRELEF benchmark in head-to-head preclinical study
+2 more records
Product overview1 text field

PRF Technologies is a diversified innovation company operating two distinct platforms: specialty pharmaceutical therapies and AI-driven energy analytics. The pharmaceutical portfolio includes PRF-110 (oil-based extended-release local anesthetic for post-operative pain) and OcuRing-K (bio-erodible intraocular ring for sustained drug release during cataract surgery, developed through majority-owned subsidiary LayerBio). The AI platform includes DeepSolar (AI-driven solar asset analytics and optimization SaaS), DeepSolar Predict (revenue optimization for renewable energy assets), and Smart TDD (solar technical due diligence service). The company was rebranded from PainReform to PRF Technologies in January 2026 to reflect this diversified strategy.

Product and service4 records
1PRF-110
CategoryPharmaceutical product
Description

Oil-based, viscous, clear extended-release formulation of ropivacaine deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. Designed for prolonged local analgesia following surgery through a single administration.

2OcuRing-K (OcuRingTD)
CategoryPharmaceutical product
Description

Bio-erodible polymer-based sustained-release intraocular ring applied to the haptic of an intraocular lens for use in cataract surgery. Delivers ketorolac (NSAID) through a single intraoperative application, eliminating the need for post-surgical eye drops. Developed through majority-owned subsidiary LayerBio, Inc.

3DeepSolar
CategoryAI SaaS platform
Description

AI-driven SaaS platform for utility-scale solar assets providing advanced forecasting, diagnostics, and data-driven operational insights. Combines localized weather intelligence, production forecasting, imbalance risk management, storage optimization, and real-time market decision support for solar plant operators.

4Smart TDD (Smart Technical Due Diligence)
CategorySolar analytics service
Description

Analytics-driven solar Technical Due Diligence service providing complete data coverage, advanced diagnostics, and rapid turnaround for investors, operators, insurers, and lenders at major asset lifecycle milestones including commissioning verification, warranty expiry checks, underperformance diagnosis, and asset acquisition support.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-03-17
Description

Commercial collaboration agreement designed to accelerate DeepSolar AI-driven solar asset optimization platform expansion across utility-scale solar portfolios. Targets multiple large-scale commercial engagements, each with minimum scope of 150 megawatts. Blade Ranger operates at intersection of renewable energy development, asset optimization, and infrastructure advisory working with solar developers, IPPs, institutional investors, and large-scale asset owners.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-18
Description

Commercial due diligence engagement for operational utility-scale solar plant in Israel. DeepSolar applies Smart TDD analytics to support structured independent technical review of solar asset condition and performance. EDF Group (Electricite De France) is one of the largest international energy companies and global leader in renewable energy.

3Shikun & Binui Energy
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-11
Description

SaaS agreement for deployment of DeepSolar analytics platform at 71 MW Satu Mare photovoltaic site in Romania. DeepSolar provides continuous analytics and performance monitoring to enhance operational visibility and support data-driven asset management throughout the project's operating life.

tipranks.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-01
Description

Majority investment acquired in August 2025. Boston-based company focused on ocular drug delivery. LayerBio develops OcuRing-K bio-erodible sustained-release intraocular ring for cataract surgery. PRF acquired LayerBio to expand pipeline and create synergies with clinical development activities.

5DeepSolar
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-01
Description

Strategic acquisition completed in March 2025 expanding PRF into AI-driven solar analytics and establishing second high-growth operating platform. AI-driven solar analytics platform for utility-scale renewable energy assets.

prf-tech.com
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2025-01-01
Description

DeepSolar is an active participant in the NVIDIA Connect Program supporting continued innovation in AI-powered renewable energy solutions. Program participation supports development of DeepSolar Predict AI-driven revenue optimization platform.

Strategic tierMinorTypeOthers
Description

Investor relations partner based in New York providing IR services for PRF Technologies. Located at 12 E. 49th Street, 18th Floor, New York, NY 10017.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Heron markets ZYNRELEF, the approved extended-release post-operative local anesthetic that PRF-110 is being benchmarked against in preclinical studies. Head-to-head competitor in the same surgical pain therapeutic category with the same ropivacaine/bupivacaine mechanism class.

TypeDirect peer
Description

Solargis provides high-resolution solar resource data, forecasting, and bankability datasets for utility-scale solar projects. Comparable to DeepSolar's localized weather intelligence and micro-climate forecast modeling capabilities.

TypeBroad incumbent
Description

Tigo Energy offers module-level power electronics and solar optimization hardware with accompanying monitoring/analytics software. Adjacent incumbent in solar optimization and asset performance, with broader hardware-based offering than DeepSolar's pure software stack.

TypeDirect peer
Description

AlsoEnergy provides asset performance monitoring, forecasting, and controls software for utility-scale solar and storage portfolios. Direct competitor to DeepSolar in the operational analytics and forecasting layer for renewable energy assets.

TypeDirect peer
Description

Aurora Solar is a leading SaaS platform for solar design, sales, and asset performance analytics. Comparable to DeepSolar as an AI-driven software platform serving utility and commercial-scale solar operators, though Aurora is more design-focused.

TypeRegional player
Description

Inseego provides IoT and SaaS-based asset monitoring and analytics for industrial/energy customers. Comparable SaaS analytics business model to DeepSolar, though with a broader industrial vertical focus rather than solar-specific.

TypeDirect peer
Description

EyePoint develops sustained-release ocular drug delivery technologies (DURYSTA, bioerodible implants) for retinal and ophthalmic indications. Directly comparable to LayerBio's OcuRing platform in technology approach and end-market focus.

TypeDirect peer
Description

Ocular Therapeutix develops sustained-release ophthalmic drug delivery platforms (including bioerodible hydrogel-based products) targeting post-cataract surgery and other ocular indications. Closely comparable to PRF's OcuRing-K bio-erodible intraocular ring for cataract surgery.

TypeDirect peer
Description

Pacira is the leader in sustained-release local anesthetic therapeutics (EXPAREL, bupivacaine liposome). It competes with PRF Technologies in the post-operative pain space and validates the commercial model of extended-release injectables for surgical sites.

TypeEmerging player
Description

Stem applies AI-driven optimization to battery energy storage and renewable assets, similar to DeepSolar Predict's storage intelligence and revenue optimization modules. Comparable AI-for-renewables business model targeting similar enterprise buyers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PRF Technologies

Specialty Pharmaceuticalsprf-tech.com

PRF Technologies (NASDAQ: PRFX) is an Israel-based diversified company developing specialty pharmaceutical drug-delivery therapies (PRF-110, OcuRing-K via LayerBio) and AI-driven SaaS for utility-scale solar asset analytics (DeepSolar). Pharmaceutical programs remain pre-commercial; DeepSolar generates early enterprise SaaS revenue.

What PRF Technologies does

PRF Technologies Ltd. (NASDAQ: PRFX), formerly PainReform Ltd., is an Israel-based, publicly traded diversified company operating two distinct platforms: specialty pharmaceutical drug-delivery therapies and AI-driven solar asset analytics. The company rebranded from PainReform in January 2026 following shareholder approval to reflect its strategic expansion. The pharmaceutical portfolio is anchored by PRF-110, a proprietary oil-based extended-release formulation of ropivacaine designed to be deposited directly into the surgical wound bed to provide sustained 72-hour local analgesia with a single intraoperative administration, and OcuRing-K, a patent-protected bio-erodible sustained-release intraocular ring delivering ketorolac for post-cataract surgery inflammation control, developed through majority-owned subsidiary LayerBio, Inc. Both programs target the FDA 505(b)(2) regulatory pathway.

The AI platform comprises DeepSolar, an AI-driven SaaS for utility-scale solar plants that combines production forecasting, storage optimization, imbalance risk management, and real-time market decision support using plant-level operational data and localized weather modeling; DeepSolar Predict, a next-generation revenue optimization module extending coverage to wind and battery storage assets; and Smart TDD, an analytics-driven technical due diligence service for solar asset lifecycle events. DeepSolar is an active participant in the NVIDIA Connect Program and has a pending patent application for solar plant micro-climate forecast modeling. Pharmaceutical products remain pre-commercial pending FDA approvals; the FDA cleared the IND for OcuRing-K Phase II in April 2026, and PRF-110 reported positive preclinical head-to-head data versus ZYNRELEF in May 2026.

The company monetizes the solar platform through annual SaaS subscriptions for DeepSolar, one-time professional services fees for Smart TDD engagements, and a channel partnership with Blade Ranger Ltd. targeting 150MW+ enterprise portfolios. Named commercial deployments include SaaS agreements with Shikun & Binui Energy (71 MW Satu Mare, Romania) and Econergy (92 MW Romania pilot), plus a Smart TDD engagement with EDF Power Solutions Israel. As of December 31, 2025, PRF Technologies held approximately $4.1M in cash, cash equivalents, short-term deposits and restricted cash against a FY2025 net loss of $4.8M (improved from $14.6M in FY2024), positive working capital of approximately $2.0M, and completed approximately $4.0M in ATM equity issuances during 2025. No revenue is disclosed. The company is headquartered in Tel Aviv with an investor relations office in New York and an R&D presence in Boston via LayerBio.

PRF Technologies firmographics

Firmographics
Name
PRF Technologies
Legal name
PRF Technologies Ltd.
Website
https://prf-tech.com
Company type
Public
Founded year
2026
Operating status
Operating
Headcount range
1–10 employees
Short description
PRF Technologies (NASDAQ: PRFX) is an Israel-based diversified company developing specialty pharmaceutical drug-delivery therapies (PRF-110, OcuRing-K via LayerBio) and AI-driven SaaS for utility-scale solar asset analytics (DeepSolar). Pharmaceutical programs remain pre-commercial; DeepSolar generates early enterprise SaaS revenue.
Ownership category
akta.pro rank

PRF Technologies industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Scientific Research and Development Services (5417), Software Publishers (513210), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYEUACAGAI
Performance Optimization & Analytics (Monitoring, Forecasting, Aerial Thermography, IV Curves)
Energy, Utilities & Environment/Electric Power Generation/Solar Power Generation (Utility-Scale PV & CSP)

Keywords

  • Extended-release pharmaceuticals
  • Post-operative pain therapy
  • Ophthalmic drug delivery
  • Solar asset analytics
  • Renewable energy forecasting

Where PRF Technologies is headquartered

Location

Headquarters

HQ city
Tel Aviv
HQ country
Israel
HQ region
Middle East

Offices3 records

Markets served

PRF Technologies business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. DeepSolar SaaS Subscriptions: SaaS subscription model for AI-driven solar analytics platform. Customers pay recurring subscription fees for access to DeepSolar platform providing continuous analytics, performance monitoring, and operational insights for solar assets.
  2. Solar Technical Due Diligence Services: One-time service fees for technical due diligence engagements including commissioning verification, warranty expiry assessments, underperformance diagnostics, and asset acquisition due diligence using Smart TDD analytics.
  3. Pharmaceutical Product Sales (Future): Revenue from sale of FDA-approved pharmaceutical products including PRF-110 for post-operative pain and OcuRing-K for cataract surgery. Products will be marketed through healthcare providers upon regulatory approval via 505(b)(2) pathway.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise SaaS for Utility-Scale Solar (150MW+)

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

PRF Technologies product offering

Product offering

Core offering

PRF Technologies develops proprietary extended-release drug-delivery platforms for specialty pharmaceuticals—PRF-110, an oil-based ropivacaine formulation for post-operative analgesia, and OcuRing-K, a bio-erodible intraocular ring for cataract surgery—and operates DeepSolar, an AI-driven SaaS platform providing forecasting, diagnostics, storage optimization, and technical due diligence for utility-scale solar assets.

Product overview

PRF Technologies is a diversified innovation company operating two distinct platforms: specialty pharmaceutical therapies and AI-driven energy analytics. The pharmaceutical portfolio includes PRF-110 (oil-based extended-release local anesthetic for post-operative pain) and OcuRing-K (bio-erodible intraocular ring for sustained drug release during cataract surgery, developed through majority-owned subsidiary LayerBio). The AI platform includes DeepSolar (AI-driven solar asset analytics and optimization SaaS), DeepSolar Predict (revenue optimization for renewable energy assets), and Smart TDD (solar technical due diligence service). The company was rebranded from PainReform to PRF Technologies in January 2026 to reflect this diversified strategy.

Differentiator

Problem solved

Functional benefit

Brands

  • PRF-110: Oil-based, viscous clear solution deposited directly into surgical wound bed for localized and extended post-operative analgesia. Based on the local anesthetic ropivacaine.
  • OcuRing
  • DeepSolar
  • DeepSolar Predict
  • Smart TDD

Products and services

  • PRF-110 Oil-based, viscous, clear extended-release formulation of ropivacaine deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. Designed for prolonged local analgesia following surgery through a single administration.
  • OcuRing-K (OcuRingTD) Bio-erodible polymer-based sustained-release intraocular ring applied to the haptic of an intraocular lens for use in cataract surgery. Delivers ketorolac (NSAID) through a single intraoperative application, eliminating the need for post-surgical eye drops. Developed through majority-owned subsidiary LayerBio, Inc.
  • DeepSolar AI-driven SaaS platform for utility-scale solar assets providing advanced forecasting, diagnostics, and data-driven operational insights. Combines localized weather intelligence, production forecasting, imbalance risk management, storage optimization, and real-time market decision support for solar plant operators.
  • Smart TDD (Smart Technical Due Diligence) Analytics-driven solar Technical Due Diligence service providing complete data coverage, advanced diagnostics, and rapid turnaround for investors, operators, insurers, and lenders at major asset lifecycle milestones including commissioning verification, warranty expiry checks, underperformance diagnosis, and asset acquisition support.

Quantifiable outcome

  • Sustained 72-hour analgesic activity comparable to approved ZYNRELEF benchmark in head-to-head preclinical study
  • +2 more outcomes

Companies that use PRF Technologies

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

PRF Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

PRF Technologies partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, strategic and minor.

  • Blade Ranger Ltd.coreGTM or Marketing Partner · 17 March 2026Commercial collaboration agreement designed to accelerate DeepSolar AI-driven solar asset optimization platform expansion across utility-scale solar portfolios. Targets multiple large-scale commercial engagements, each with minimum scope of 150 megawatts. Blade Ranger operates at intersection of renewable energy development, asset optimization, and infrastructure advisory working with solar developers, IPPs, institutional investors, and large-scale asset owners.
  • EDF Power Solutions IsraelcoreTechnology or Integration · 18 February 2026Commercial due diligence engagement for operational utility-scale solar plant in Israel. DeepSolar applies Smart TDD analytics to support structured independent technical review of solar asset condition and performance. EDF Group (Electricite De France) is one of the largest international energy companies and global leader in renewable energy.
  • Shikun & Binui EnergycoreTechnology or Integration · 11 February 2026SaaS agreement for deployment of DeepSolar analytics platform at 71 MW Satu Mare photovoltaic site in Romania. DeepSolar provides continuous analytics and performance monitoring to enhance operational visibility and support data-driven asset management throughout the project's operating life.
  • LayerBio, Inc.coreStrategic or Co-development Partner · 1 August 2025Majority investment acquired in August 2025. Boston-based company focused on ocular drug delivery. LayerBio develops OcuRing-K bio-erodible sustained-release intraocular ring for cataract surgery. PRF acquired LayerBio to expand pipeline and create synergies with clinical development activities.
  • DeepSolarcoreStrategic or Co-development Partner · 1 March 2025Strategic acquisition completed in March 2025 expanding PRF into AI-driven solar analytics and establishing second high-growth operating platform. AI-driven solar analytics platform for utility-scale renewable energy assets.
  • NVIDIA Connect ProgramstrategicTechnology or Integration · 1 January 2025DeepSolar is an active participant in the NVIDIA Connect Program supporting continued innovation in AI-powered renewable energy solutions. Program participation supports development of DeepSolar Predict AI-driven revenue optimization platform.
  • Crescendo Communications, LLCminorOthersInvestor relations partner based in New York providing IR services for PRF Technologies. Located at 12 E. 49th Street, 18th Floor, New York, NY 10017.

Scale indicators7 records

Recent moves7 records

Expansion highlights8 records

PRF Technologies competitors and assessment

Company assessment

Direct peers

  • Heron Therapeutics: Heron markets ZYNRELEF, the approved extended-release post-operative local anesthetic that PRF-110 is being benchmarked against in preclinical studies. Head-to-head competitor in the same surgical pain therapeutic category with the same ropivacaine/bupivacaine mechanism class.
  • Solargis: Solargis provides high-resolution solar resource data, forecasting, and bankability datasets for utility-scale solar projects. Comparable to DeepSolar's localized weather intelligence and micro-climate forecast modeling capabilities.
  • AlsoEnergy: AlsoEnergy provides asset performance monitoring, forecasting, and controls software for utility-scale solar and storage portfolios. Direct competitor to DeepSolar in the operational analytics and forecasting layer for renewable energy assets.
  • Aurora Solar: Aurora Solar is a leading SaaS platform for solar design, sales, and asset performance analytics. Comparable to DeepSolar as an AI-driven software platform serving utility and commercial-scale solar operators, though Aurora is more design-focused.
  • EyePoint Pharmaceuticals: EyePoint develops sustained-release ocular drug delivery technologies (DURYSTA, bioerodible implants) for retinal and ophthalmic indications. Directly comparable to LayerBio's OcuRing platform in technology approach and end-market focus.
  • Ocular Therapeutix: Ocular Therapeutix develops sustained-release ophthalmic drug delivery platforms (including bioerodible hydrogel-based products) targeting post-cataract surgery and other ocular indications. Closely comparable to PRF's OcuRing-K bio-erodible intraocular ring for cataract surgery.
  • Pacira BioSciences: Pacira is the leader in sustained-release local anesthetic therapeutics (EXPAREL, bupivacaine liposome). It competes with PRF Technologies in the post-operative pain space and validates the commercial model of extended-release injectables for surgical sites.

Broad incumbents

  • Tigo Energy: Tigo Energy offers module-level power electronics and solar optimization hardware with accompanying monitoring/analytics software. Adjacent incumbent in solar optimization and asset performance, with broader hardware-based offering than DeepSolar's pure software stack.

Regional players

  • Inseego Corp: Inseego provides IoT and SaaS-based asset monitoring and analytics for industrial/energy customers. Comparable SaaS analytics business model to DeepSolar, though with a broader industrial vertical focus rather than solar-specific.

Emerging players

  • Stem Inc: Stem applies AI-driven optimization to battery energy storage and renewable assets, similar to DeepSolar Predict's storage intelligence and revenue optimization modules. Comparable AI-for-renewables business model targeting similar enterprise buyers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

PRF Technologies social profiles

Digital presence

PRF Technologies compliance and trust

Trust signal

Compliance1 record

PRF Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PRF Technologies leadership team

Management profile

Number of profiles

Profiles8 records

PRF Technologies subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

PRF Technologies funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PRF Technologies M&A and investment

M&A and investment

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PRF Technologies

What does PRF Technologies do?

PRF Technologies develops proprietary extended-release drug-delivery platforms for specialty pharmaceuticals—PRF-110, an oil-based ropivacaine formulation for post-operative analgesia, and OcuRing-K, a bio-erodible intraocular ring for cataract surgery—and operates DeepSolar, an AI-driven SaaS platform providing forecasting, diagnostics, storage optimization, and technical due diligence for utility-scale solar assets.

Is PRF Technologies a public or private company?

PRF Technologies is a public company. It is classified as public and is currently operating.

When was PRF Technologies founded?

PRF Technologies was founded in 2026. It employs 1 to 10 people.

Where is PRF Technologies based?

PRF Technologies is headquartered in Tel Aviv, Israel, in the Middle East region.

How does PRF Technologies make money?

Three revenue lines are on record. DeepSolar SaaS Subscriptions are the primary driver. The others are solar Technical Due Diligence Services and pharmaceutical Product Sales (Future).

Who are PRF Technologies's main competitors?

Direct peers on record are Heron Therapeutics, Solargis, AlsoEnergy, Aurora Solar, EyePoint Pharmaceuticals, Ocular Therapeutix and Pacira BioSciences. Tigo Energy is listed as a broad incumbent. Inseego Corp is listed as a regional player. Stem Inc is listed as an emerging player.

Does PRF Technologies have an API?

No public API is recorded for PRF Technologies.

What industry is PRF Technologies in?

PRF Technologies's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals, with a secondary code of EUACAGAI, Performance Optimization & Analytics (Monitoring, Forecasting, Aerial Thermography, IV Curves). Its NAICS code is 5417 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comPRF Technologies faces Nasdaq delisting over share pricePRF Technologies received a Nasdaq delisting determination on November 9 after its share price closed below $1.00 for 30 consecutive days. The company requested a hearing by November 16, which suspends the delisting, and plans to present a compliance plan that may include another reverse stock split. The panel can grant an exception up to May 8, 2027.YahooPRF Technologies Receives Nasdaq Delisting Determination Regarding Minimum Bid Price Requirement and Requests a HearingPRF Technologies received a Nasdaq delisting determination because its ordinary shares traded below $1 for 30 consecutive business days. The company requested a hearing, which stays the delisting, and plans to present a compliance plan, possibly including a reverse share split. The Panel may grant an exception up to May 8, 2027.Business & FinancialPRF Technologies Receives Nasdaq Delisting Determination Regarding Minimum Bid Price Requirement And Requests A HearingPRF Technologies received a Nasdaq delisting determination for falling below the $1 minimum bid price for 30 consecutive days. The company requested a hearing, which stays the delisting pending the panel's decision. It plans to present a compliance plan, possibly including a reverse share split.TradingViewPRF Technologies (PRFX) Proposes $1.0M GridFeed Sale to DotzPRF Technologies signed a non-binding term sheet to sell GridFeed to Dotz for $1.0M, with PRF investing $250K in Dotz's A$2.0M placement. The deal is subject to due diligence, board approvals, and definitive agreements, and could shift platform operating costs to Dotz.Stock TitanPRF Technologies, Dotz sign nonbinding $1M term sheetPRF Technologies and Dotz Nano signed a non-binding term sheet for Dotz to acquire PRF's GridFeed AI energy platform for $1 million. Dotz would launch GridFeed under an exclusive license, with PRF taking a $250,000 equity position in Dotz. The deal is subject to due diligence and board approvals.GlobeNewswirePRF Technologies Issues Letter to Shareholders Highlighting $11.0 Million Cash Position, Entering Phase 2 Trial of OcuRing™-K and GridFeed™ Opportunity in AI Data Center PowerPRF Technologies issued a shareholder letter reporting approximately $11.0 million in cash and $2.5 million in liabilities as of September 30, 2026, with a consolidated operating loss of $3.7 million for the nine months ended that date. The company plans to start patient enrollment in the U.S. Phase 2 trial of OcuRing-K before year-end and will establish GridFeed as a standalone subsidiary to pursue data center power optimization.Stock TitanPRF Technologies Explores AI Data Center Power MarketPRF Technologies is exploring the AI and hyperscale data center market with its GridFeed AI energy optimization platform. The company cites IEA projections of global data center electricity consumption doubling to 950 TWh by 2030, with AI-focused data centers expected to triple. GridFeed's optimization engine could help operators manage power capacity and costs.AInvestPRF Technologies' GridFeed: An AI-Energy Story Played Inside a Company Worth Less Than Its CashPRF Technologies plans to carve out its AI energy trading platform GridFeed into a standalone subsidiary to pursue strategic alliances. The company trades at about $3.3 million, below its $11.6 million cash, and funds itself via a discounted share purchase agreement with Yorkville. The move creates optionality but does not guarantee a partner.Quiver QuantitativePRF Technologies Issues Letter to Shareholders Highlighting Financing, Clinical Progress and DeepSolar Momentum | Quiver QuantitativePRF Technologies Ltd. raised $10 million through its equity line facility on May 28, 2026, substantially strengthening its balance sheet and providing resources to accelerate existing businesses while pursuing strategic growth opportunities. The company's biotechnology subsidiary LayerBio is advancing preparations for a planned Phase 2 clinical trial of OcuRing™-K and reported expanded preclinical results for PRF-110 demonstrating sustained 72-hour analgesic activity comparable to approved benchmarks. Additionally, DeepSolar validated its Predict™ platform with real-world European market data, expanded its Battery-to-Revenue Intelligence features, joined the NVIDIA Connect program, and will showcase GridFeed™ at Energy Trading Week Europe 2026.YahooPRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy PlatformsPRF Technologies Ltd. raised $10 million through its equity line facility on May 28, 2026, substantially strengthening its balance sheet and providing increased strategic flexibility. LayerBio is advancing operational and clinical preparations for the planned Phase 2 clinical trial of OcuRing™-K, while preclinical results for PRF-110 demonstrated sustained 72-hour analgesic activity comparable to an approved extended-release benchmark. DeepSolar validated its Predict™ platform with real-world European market data, expanded its offerings with Battery-to-Revenue Intelligence, and joined the NVIDIA Connect program as it moves toward commercial launch.